RxDoctor Payments Data

Heather Abdalla

Family · Quakertown, PANPI 1386179489

Payments from drug & device makers

$1,592in general payments, 2019–2025

Across 52 payments — averaging $30.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$862
  • E.r. Squibb & Sons, L.L.C.$190
  • AstraZeneca$102
  • SK Life Science, Inc.$100
  • Neurocrine Biosciences, Inc.$98
  • Amgen$96
  • plus $143 from 2 others

What the payments were for

  • Food & beverage$1,592100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)42$862
E.r. Squibb & Sons, L.L.C.2$190
AstraZeneca1$102
SK Life Science, Inc.2$100
Neurocrine Biosciences, Inc.1$98
Amgen1$96
Biohaven Pharmaceuticals, Inc.1$80
Microtransponder, Inc.2$63

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,592 in reported general payments places this provider in the 80th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$26,788
Medicare patients
172
Services billed
235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate22$171,744
NuplazidPimavanserin Tartrate26$123,467
UbrelvyUbrogepant50$63,138
RytaryCarbidopa/Levodopa30$44,827
Nurtec OdtRimegepant Sulfate22$34,037
QuliptaAtogepant20$20,064
Emgality PenGalcanezumab-Gnlm27$19,916
Carbidopa-LevodopaCarbidopa/Levodopa173$9,049
Rasagiline Mesylate41$8,701
Entacapone24$3,830
AmantadineAmantadine Hcl26$2,618
Carbidopa-Levodopa ErCarbidopa/Levodopa35$2,053
Selegiline Hcl15$1,518
Memantine Hcl56$1,037
Donepezil Hcl69$998

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$98$171,74422 claims
AbbVieUbrelvy, Qulipta$862$83,20270 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,717 family providers in Pennsylvania.

Other family in Quakertown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →